Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension

BACKGROUND: A 6-month phase 2 study of fingolimod demonstrated efficacy and safety in Japanese patients with relapsing-remitting multiple sclerosis (MS). Here we report a 6-month observational extension that evaluated efficacy and safety in patients who received fingolimod continuously for 12 months...

Descripción completa

Detalles Bibliográficos
Autores principales: Kira, Jun-ichi, Itoyama, Yasuto, Kikuchi, Seiji, Hao, Qi, Kurosawa, Takayoshi, Nagato, Kazuo, Tsumiyama, Isao, von Rosenstiel, Philipp, Zhang-Auberson, Lixin, Saida, Takahiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3911956/
https://www.ncbi.nlm.nih.gov/pubmed/24475777
http://dx.doi.org/10.1186/1471-2377-14-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3911956/
https://www.ncbi.nlm.nih.gov/pubmed/24475777
http://dx.doi.org/10.1186/1471-2377-14-21

Ejemplares similares